Heart Disease and Cellular Therapy: Start of Phase III Clinical Trial
"PERFECT" Using Autologous CD133+ Bone Marrow Stem Cells
BERGISCH GLADBACH,
PERFECT is a randomized, prospective, double-blind, placebo-controlled, multi-center trial, and it is the first phase III trial evaluating the efficacy of a cellular therapy product in cardiac disease. The trial is part of a large joint research project among the Heart Centers in Rostock,
About Miltenyi Biotec
Miltenyi Biotec is a biotechnology company focused on the development of cellular therapies and biomedical research. The company is working with clinical investigators worldwide to develop cellular therapeutics for unmet medical needs and is committed to delivering the promise of cellular medicine in the fields of organ regeneration, immune modulation, and transplantation.
For further information: Prof. Dr. Uwe Heinlein, Corporate Communications, Miltenyi Biotec GmbH, Friedrich-Ebert-Str. 68, 51429 Bergisch Gladbach, Germany, Phone +49-2204-8306-6590, e-mail [email protected]
Share this article